NAD+ IV vs Subcutaneous vs Oral Troche
All three are ways clinicians may deliver NAD+. IV infusions are administered in-clinic over an extended visit. Subcutaneous injections are self-administered between visits. Oral troches dissolve in the mouth for buccal absorption. Each route has a different bioavailability profile, schedule, and supply footprint, and route selection is decided by the prescribing clinician.
What's being compared
In-clinic intravenous infusion administered over an extended visit.
Self-administered subcutaneous injection between clinician visits.
Buccal/sublingual troche that dissolves in the mouth for mucosal absorption.
Side-by-side comparison
| Attribute | IV | Subcutaneous | Oral troche |
|---|---|---|---|
| Route | Intravenous infusion. | Subcutaneous injection. | Oral troche dissolved buccally or sublingually. |
| Where it is given | Administered in a clinic or infusion center under clinician oversight. | Self-administered at home after clinician training. | Self-administered at home; no injection required. |
| Absorption profile | Direct delivery into the systemic circulation; bypasses absorption barriers. | Steady absorption from the subcutaneous depot; lower per-dose volume than IV. | Buccal/sublingual mucosa absorption; oral bioavailability of NAD+ varies by formulation and is discussed in the literature. |
| Typical schedule | Single or series of in-clinic infusions, spaced per the clinician's protocol. | Daily or several-times-weekly injections per the clinician's protocol. | Daily troche use per the clinician's protocol. |
| Supplies and storage | IV line, infusion bag, and clinic monitoring; no take-home supplies. | Vial, syringes, needles, sharps disposal, and refrigeration per labeling. | Troches in a labeled container; storage per labeling. |
| Patient training | No patient injection technique required; handled in-clinic. | Patient training on injection technique, site rotation, and sharps disposal. | Minimal; instructions on placement and dissolution time. |
| Tolerability discussed in the literature | Infusion-related sensations (flushing, chest pressure, nausea) are commonly discussed in clinical practice and managed by slowing the infusion rate. | Local injection-site reactions are the main category discussed in clinical practice. | Local oral sensations are the main category discussed in clinical practice. |
| Regulatory status | No FDA-approved NAD+ finished product for IV use; preparations are dispensed by 503A/503B compounding pharmacies on a clinician-directed basis. | No FDA-approved NAD+ finished product for subcutaneous use; preparations are dispensed by 503A/503B compounding pharmacies on a clinician-directed basis. | No FDA-approved NAD+ finished product for oral use; troches are dispensed by 503A/503B compounding pharmacies on a clinician-directed basis. |
| Typical clinician use case | Considered when a clinician wants a supervised in-clinic NAD+ administration with controlled rate. | Considered when a clinician wants between-visit dosing the patient can manage at home. | Considered when patient preference favors a non-injectable route and the clinical question fits an oral protocol. |
| Regen Therapy availability | Available through Regen Therapy clinic partners that operate infusion services. | Compounded subcutaneous NAD+ preparations are dispensed by Wells Pharmacy Network when clinically appropriate after evaluation. | Oral NAD+ preparations are available through Wells Pharmacy Network when clinically appropriate after evaluation. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
An IV infusion is the route designed for in-clinic delivery, with the clinician controlling rate and monitoring tolerability throughout the visit.
A subcutaneous protocol is the option clinicians most often consider for ongoing at-home NAD+ administration after the initial training.
An oral NAD+ troche is the non-injectable option; whether it is the right fit is a clinical judgment based on the patient's situation.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Is IV NAD+ stronger than subcutaneous or oral?
It is not a stronger-versus-weaker comparison. Each route delivers NAD+ on a different time profile and at a different per-administration dose. The clinician chooses based on the goal of the protocol, not on a single ranking.
Why does IV NAD+ take so long?
IV NAD+ infusions are typically run slowly because faster rates are commonly associated with infusion-related sensations such as flushing, chest pressure, or nausea in clinical practice. Slowing the infusion is the standard way clinicians manage tolerability.
Is subcutaneous NAD+ the same dose as IV?
No. Per-administration doses for subcutaneous NAD+ are generally smaller than IV doses and are spread across more frequent administrations. The exact schedule is set by the prescribing clinician.
Are NAD+ troches absorbed at all?
Troches are formulated for buccal/sublingual absorption across the oral mucosa. Bioavailability of NAD+ via oral routes varies by formulation and is discussed in the literature; whether a troche is the right fit is a clinical decision.
Are any of these NAD+ products FDA-approved?
No. There is no FDA-approved finished NAD+ product for IV, subcutaneous, or oral use at the time of writing. NAD+ preparations are compounded by 503A or 503B pharmacies on a patient-specific prescription.
How is the route chosen?
The prescribing clinician selects the route based on the clinical question, the patient's history and preferences, the available formulations through the compounding pharmacy, and the practical setting where the protocol will be administered.